Today: 9 June 2026
Oracle stock price rises as $50 billion funding plan eases AI buildout fears
2 February 2026
2 mins read

Oracle stock price rises as $50 billion funding plan eases AI buildout fears

NEW YORK, February 2, 2026, 13:33 EST — Regular session

  • Oracle shares climbed roughly 1.7% in early afternoon trading following its announcement of a debt-and-equity raise planned for 2026
  • The software maker is presenting the plan as a way to shore up its balance sheet amid rapid cloud expansion.
  • Investors juggle the trade-off between funding relief and the threat of dilution, while also grappling with doubts about AI returns

Oracle shares edged up Monday, reacting to the company’s announcement of a plan to raise up to $50 billion this year aimed at funding a costly cloud expansion. The stock gained roughly 1.7%, closing near $167.43, after fluctuating between $155.90 and $175.62 during the session.

Oracle on Sunday detailed plans for a $45 billion to $50 billion financing package aimed at calendar 2026, aiming to address concerns over funding additional data-center capacity.

Why it matters now: investors are quick to slam companies that hype artificial intelligence infrastructure without delivering near-term results, especially as debt levels and cash demands rise. Oracle’s recent fundraising effort also gauges how willing the market is to back AI-related credit, after the cost to insure its debt jumped sharply in recent months, according to Barron’s.

Oracle plans to fund about half of its 2026 financing with equity, including an at-the-market program capped at $20 billion. The remainder will come from a single investment-grade senior unsecured bond issuance early next year. Goldman Sachs is set to lead the bond transaction, with Citigroup heading the equity and mandatory convertible preferred offerings, Oracle said.

Oracle filed a preliminary prospectus supplement on Monday for 100 million depositary shares linked to its Series D mandatory convertible preferred stock, a U.S. SEC filing reveals. Each depositary share corresponds to a 1/2,000th interest in a preferred share and carries a $50 liquidation preference, according to the document.

Analysts see Oracle’s package as a clear signal to bond investors and rating agencies: the company plans to defend its investment-grade rating, even if that means relying more on equity. “Oracle is not only saying they’re committed to investment-grade debt, but they are sending a clear message to bond investors and the rating agencies that they are,” Guggenheim analysts noted. Barclays added that the blend of equity and mandatory convertible preferred shares could ease debt levels and bolster the balance sheet. Following the announcement, Oracle’s credit-default swaps—basically default insurance—tightened. One strategist pointed out that Oracle’s prospects appear “heavily tied to OpenAI,” keeping investor nerves on edge. Reuters

Oracle has lagged behind Microsoft and Amazon in the cloud space, but its drive to rent out computing power is picking up pace as clients scramble for AI resources. Now, financing details are moving markets rather than fading into the background.

But the plan carries clear risks. Issuing new shares dilutes current shareholders, and the returns on AI investments remain patchy throughout the sector. Should demand falter or pricing weaken, Oracle might find itself stuck with a costly expansion and little margin for mistakes.

Traders are eyeing pricing and demand signals on the preferred offering closely, while also looking for clues from credit markets as Oracle gears up for its one-time bond sale later this year.

Wall Street this week is zeroing in again on heavyweight earnings and crucial economic data, as investors weigh if AI-driven spending can withstand closer inspection amid tighter funding.

Stock Market Today

  • $150M Cancer Proteomics Deal Spurs New NYSE Listing
    June 9, 2026, 9:34 AM EDT. A $150 million deal in functional proteomics, the study of protein functions and interactions critical for drug development, has led to the spin-out of a new company set to list on the New York Stock Exchange (NYSE). The company focuses on advanced cancer treatments including antibody-drug conjugates-targeted therapies combining antibodies with cell-killing agents to attack tumors precisely. Immunotherapies and targeted therapies featured in the pipeline aim to harness and guide the immune system to combat cancer effectively. Filing of the registration statement with regulators marks a key step toward public investment, enabling transparency. This development highlights the growing financial and clinical importance of proteomics in oncology and the biotech sector.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cisco stock pops to a fresh 52-week high — here’s what Wall Street is watching next
Previous Story

Cisco stock pops to a fresh 52-week high — here’s what Wall Street is watching next

Why Coherent stock is jumping today as a unit sale closes and earnings loom
Next Story

Why Coherent stock is jumping today as a unit sale closes and earnings loom

Go toTop